KRAS and cancer: A promising strategy to target KRAS-driven tumors is to exploit cancer cell vulnerabilities contextually co-opted by mutant KRAS, in light of the concept that mutant KRAS alter physiological biochemical networks and induces cellular stresses, rendering KRAS-mutant cancer particularly susceptible to inhibition of stress-remedy mechanisms [12–14].